Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17382377 
Li QJ, et al. (2007) miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129, 147-61 17382377
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T203-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  T lymphocyte-lymph node
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
miRNA increase miR-181a
anti-CD3 increase
miRNA anti-CD3 augment treatment-induced increase miR-181a

Y205-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  T lymphocyte-lymph node
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
miRNA increase miR-181a
anti-CD3 increase
miRNA anti-CD3 augment treatment-induced increase miR-181a

T183-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  T lymphocyte-lymph node
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
miRNA increase miR-181a
anti-CD3 increase
miRNA anti-CD3 augment treatment-induced increase miR-181a

Y185-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  T lymphocyte-lymph node
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
miRNA increase miR-181a
anti-CD3 increase
miRNA anti-CD3 augment treatment-induced increase miR-181a

Y394-p - Lck (mouse)
Orthologous residues
Lck (human): Y394‑p, Lck (mouse): Y394‑p, Lck (rat): Y394‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  T lymphocyte-lymph node
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
miRNA increase miR-181a
miRNA MKP-3 (mouse) inhibit treatment-induced increase
miRNA SHP-2 (mouse) no effect upon treatment-induced increase

Y505-p - Lck (mouse)
Orthologous residues
Lck (human): Y505‑p, Lck (mouse): Y505‑p, Lck (rat): Y505‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  T lymphocyte-lymph node
 Cellular systems studied:  primary cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
miRNA no change compared to control miR-181a


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.